GlaxoSmithKline [NYSE:GSK] issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia? (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes:
The Director of the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) challenged psychiatrists to learn more about the importance of substance abuse as a factor in the diagnosis and treatment of mental illnesses.
Human umbilical cord blood has received increased attention in recent years as a viable source for pluripotent stem cells that can be used in a wide array of applications.
Currently, 5-aminosalicylic acid (5-ASA) is the most common treatment for ulcerative colitis (UC), a form of inflammatory bowel disease (IBD).
Complex anal fistulas, abnormal connections between the anal canal and the skin, is a chronic and highly debilitating condition affecting primarily young people and seriously compromising their quality of life.
Patterns of human behavior and movement in crowded cities — the tipping point at which agitated crowds become anti-social mobs, the configuration of civic areas as defensible spaces that also promote free speech, the design of retail space that fosters active walking — are at the core of an immersive 3-D computational model under development by an Arizona State University geographer.
In the largest and most rigorous U.S. trial comparing two traditional operations for stress urinary incontinence (SUI) in women, a team of urologists and urogynecologists supported by the National Institutes of Health (NIH) has found that a sling procedure helps more women achieve dryness than the Burch technique.
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes.
Treatment with a commonly used drug slows the decline in lung function in patients with chronic obstructive pulmonary disease (COPD), according to results from the TORCH (TOwards a Revolution in COPD Health) study presented at the American Thoracic Society 2007 International Conference, on Tuesday, May 22.
Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma, announced today the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair? Bronchial Thermoplasty System. Bronchial Thermoplasty is a non-drug treatment for asthma under clinical investigation in the United States.